Silence Therapeutics plc (SLN)

Etorro trading 970x250
Silence Therapeutics plc (SLN) Logo

About Silence Therapeutics plc

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom. Address: 72 Hammersmith Road, London, United Kingdom, W14 8TH

Silence Therapeutics plc News and around…

Latest news about Silence Therapeutics plc (SLN) common stock and company :

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference
18 May, 2022 FinancialContent

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference, on May 23-26, 2022.

Silence Therapeutics Reports First Quarter 2022 Results
16 May, 2022 FinancialContent

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today reported its financial results for the first quarter ended March 31, 2022 and reviewed recent business highlights.

12 Health Care Stocks Moving In Tuesday's Intraday Session
10 May, 2022 FinancialContent

Gainers Biohaven Pharma Hldgs (NYSE:BHVN) stock moved upwards by 70.0% to $141.34 during Tuesday's regular session. ...

74 Biggest Movers From Yesterday
29 Apr, 2022 FinancialContent

Gainers T Stamp Inc. (NASDAQ: IDAI) shares surged 123.8% to close at $4.70 on Thursday. Trust Stamp reported the launch of its ...

12 Health Care Stocks Moving In Thursday's Intraday Session
28 Apr, 2022 FinancialContent

Gainers Statera BioPharma (NASDAQ:STAB) stock moved upwards by 119.1% to $0.46 during Thursday's regular session. As ...

61 Biggest Movers From Yesterday
28 Apr, 2022 FinancialContent

Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed ...

38 Stocks Moving In Wednesday's Mid-Day Session
27 Apr, 2022 FinancialContent

Gainers Vivakor, Inc. (NASDAQ: VIVK) gained 154% to $4.3550 after the company announced it has signed a 10-year contract with ...

Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
25 Apr, 2022 FinancialContent

Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of an undisclosed preclinical milestone.

Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference
06 Apr, 2022 FinancialContent

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the 21st Annual Needham Virtual Healthcare Conference at 8:00 a.m. Eastern Time on Thursday, April 14, 2022.

Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)
03 Apr, 2022 FinancialContent

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced publication of results from the phase 1 APOLLO trial of SLN360, an siRNA targeting lipoprotein(a) (“Lp(a)”), in the latest issue of the Journal of the American Medical Association (JAMA), linked here.

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting
03 Apr, 2022 FinancialContent

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today presented detailed results from its phase 1 APOLLO trial that showed SLN360, an investigational siRNA, reduced levels of lipoprotein(a) (“Lp(a)”), an important genetic risk factor for heart disease, by up to 98% in healthy adults with high Lp(a).

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
31 Mar, 2022 FinancialContent

Upgrades Raymond James upgraded the previous rating for Starwood Property Trust Inc (NYSE:STWD) from Outperform to Strong Buy. For the ...

Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
23 Mar, 2022 FinancialContent

Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, and Mallinckrodt plc (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced filing of a clinical trial application (CTA) for SLN501, an siRNA targeting the complement C3 protein, triggering a $3 million milestone payment to Silence.

Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results
17 Mar, 2022 FinancialContent

Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results

Earnings Scheduled For March 17, 2022
17 Mar, 2022 FinancialContent

Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth ...

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022
02 Mar, 2022 FinancialContent

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022

Stocks That Hit 52-Week Lows On Tuesday
22 Feb, 2022 FinancialContent

During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week ...

Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
21 Feb, 2022 FinancialContent

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Craig Tooman, previously Chief Financial Officer (“CFO”), has been appointed President, Chief Executive Officer (“CEO”) and Board member of Silence, and Mark Rothera has stepped down as President, CEO and Board member, effective immediately. Rhonda Hellums, previously Vice President, Finance, has been appointed CFO.

8 Medical Stocks to Buy According to Mitchell Blutt’s Consonance Capital
15 Feb, 2022 Yahoo! Finance

In this article, we will be looking at the 8 medical stocks to buy according to Mitchell Blutt’s Consonance Capital. You can skip our detailed analysis of these stocks and head directly to 3 Medical Stocks to Buy According to Mitchell Blutt’s Consonance Capital. Mitchell Blutt is an American physician-businessman. He is one of the […]

Silence Therapeutics Posts First Human Data For Cardiovascular Candidate
09 Feb, 2022 FinancialContent

Silence Therapeutics plc(NASDAQ: SLN) showed that its RNAi technology couldreduce a patient's lp(a) levels by 98% at a ...

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
09 Feb, 2022 FinancialContent

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo
26 Jan, 2022 FinancialContent

Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at ACC Meeting in April 2022.

51 Biggest Movers From Yesterday
26 Jan, 2022 FinancialContent

Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline ...

Silence Therapeutics’ Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to Oligonucleotide Therapeutics Society Board of Directors
18 Jan, 2022 FinancialContent

Dr. Marie Wikström Lindholm, SVP, Molecular Design at Silence Therapeutics, elected to Board of Directors of Oligonucleotide Therapeutics Society.

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference
05 Jan, 2022 Yahoo! Finance

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference 5 January 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a fireside chat during the H.C. Wainwright BioConnect Virtual Conferen

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases
12 Dec, 2021 Yahoo! Finance

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases Data presented at 2021 ASH annual meeting showed durable reductions in serum iron and transferrin saturation, strong safety profile and long duration of action Data support ongoing studies in patients with thalassemia and myelodysplastic syndrome and a new planned study in polycythemia vera 12 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a lead

Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
01 Dec, 2021 Yahoo! Finance

1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Deep Track Capital, a U.S. investment firm focused exclusively on the life sciences industry, purchased approximately $22 million of American Depository Shares (ADSs) in Silence from existing shareholder

Silence Therapeutics Begins Exclusive Nasdaq Trading
30 Nov, 2021 Yahoo! Finance

Silence Therapeutics Begins Exclusive Nasdaq Trading 30 November 2021 LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the cancellation of admission of its ordinary shares of nominal value £0.05 each (the “Ordinary Shares”) to trading on AIM (the “AIM Delisting”) was e

Silence Therapeutics to Present at Jefferies London Healthcare Conference
11 Nov, 2021 Yahoo! Finance

Silence Therapeutics to Present at Jefferies London Healthcare Conference 11 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies London Healthcare Conference being held November 16-18, 2021. The on-dema

The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
15 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of ...

Silence Therapeutics plc (SLN) is a NASDAQ Common Stock listed in , ,

970x250